Erik Petter Wingstrand
Presidente presso T-Bolaget AB
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Henrik Johan Wingstrand | M | 43 |
T-Bolaget AB
T-Bolaget AB Financial ConglomeratesFinance T-Bolaget AB engages in investment and trading of securities, for a limited and closed group of owners. The company was founded on December 15, 1958 and is headquartered in Gothenburg, Sweden. | - |
Karin Helena Johansson Wingstrand | F | 67 |
T-Bolaget AB
T-Bolaget AB Financial ConglomeratesFinance T-Bolaget AB engages in investment and trading of securities, for a limited and closed group of owners. The company was founded on December 15, 1958 and is headquartered in Gothenburg, Sweden. | 23 anni |
Olof Gustaf Paulus Isaksson | M | 81 |
Internetmedicin Holding AB
| - |
Åsa Riisberg | F | 50 |
Internetmedicin Holding AB
| 3 anni |
Thérèse Elmquist | F | - |
Jumperfabriken Sweden AB
Jumperfabriken Sweden AB Apparel/Footwear RetailRetail Trade Jumperfabriken Sweden AB is a Swedish company that sells men's and women's clothing and accessories through an online platform. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Hans Marcus Bosson | M | 56 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 12 anni |
Jan Anders Vedin | M | 82 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 anni |
Kent Alan Gossett | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 anni |
Staffan Lindstrand | M | 62 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Jonas Frick | M | 66 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Johan Rutger Christenson | M | 65 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 5 anni |
Jens W. Kindtler | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 7 anni |
Jonas Karl Olaf Brambeck | M | 66 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 anni |
Sven-Erik Dahlén | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 5 anni |
Claes Lundberg | M | 73 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 6 anni |
Deborah Harland | M | 64 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Sture Jan-Gunnar Gustafsson | M | 74 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Stefan Persson | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 9 anni |
Bengt Sparf | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 anni |
Vidar Wendel-Hansen | M | 65 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 5 anni |
Helena Lindberg | F | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Svezia | 21 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Erik Petter Wingstrand
- Contatti personali